IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE

In re:	Chapter 11
Apple Tree Life Sciences, Inc., *et al.*,[1]	Case No. 25-12177 (LSS)
Debtors.	(Jointly Administered)

NOTICE OF AGENDA OF MATTERS SCHEDULED
FOR HEARING ON OCTOBER 28, 2026 AT 10:00 A.M. (ET)

This proceeding will be conducted in-person and remotely via Zoom. Please refer to Judge Silverstein's Chambers Procedures (https://www.deb.uscourts.gov/judge-laurie-selber-silverstein) and the Court's website (http://www.deb.uscourts.gov/ecourt-appearances) for information on who may participate remotely, the method of allowed participation (video or audio), Judge Silverstein's expectations of remote participants, and the advance registration requirements.

Registration is required by one hour prior the hearing unless otherwise noticed using the *eCourtAppearances* tool available on the Court's website.

RESOLVED MATTERS:

1. Debtors' Motion for Entry of an Order (I) Extending Time to File Rule 2015.3 Financial Reports and (II) Granting Related Relief [Docket No. 1175 – filed September 28, 2026]

   Response/Objection Deadline: October 13, 2026 at 4:00 p.m. (ET)

   Related Documents:

   A. Certificate of No Objection Regarding Debtors' Motion for Entry of an Order (I) Extending Time to File Rule 2015.3 Financial Reports and (II) Granting Related Relief [Docket No. 1211 – filed October 14, 2026]

[1] The Debtors in these chapter 11 cases, along with the last four digits of each Debtor's federal tax identification number include: Apple Tree Life Sciences, Inc. (4506); ATP Life Science Ventures, L.P. (8224); ATP III GP, Ltd. (6091); Apertor Pharmaceuticals, Inc. (3161); Initial Therapeutics, Inc. (2453); Marlinspike Therapeutics, Inc. (4757); Red Queen Therapeutics, Inc. (8563); Evercrisp Biosciences, Inc. (4437); Nine Square Therapeutics, Inc. (4503); and Nereid Therapeutics Incorporated (8493). The location of the Debtors' service address in these chapter 11 cases is 230 Park Avenue, Suite 2800, New York, NY 10169.

2512177261026000000000001

B. Order (I) Extending Time to File Rule 2015.3 Financial Reports and (II) Granting Related Relief [Docket No. 1214 – entered October 15, 2026]

Responses/Objections Received: None.

Status: The order has been entered. No hearing is necessary.

2. Debtors' Third Motion Pursuant to Federal Rule of Bankruptcy Procedure 9006(b) for an Order Enlarging the Time to File Notices of Removal of Related Proceedings [Docket No. 1189 – filed October 1, 2026]

Response/Objection Deadline: October 15, 2026 at 4:00 p.m. (ET)

Related Documents:

A. Certificate of No Objection Regarding Debtors' Third Motion Pursuant to Federal Rule of Bankruptcy Procedure 9006(b) for an Order Enlarging the Time to File Notices of Removal of Related Proceedings [Docket No. 1222 – filed October 16, 2026]

B. Order Granting Debtors' Third Motion Pursuant to Federal Rule of Bankruptcy Procedure 9006(b) for an Order Enlarging the Time to File Notices of Removal of Related Proceedings [Docket No. 1233 – entered October 20, 2026]

Responses/Objections Received: None.

Status: The order has been entered. No hearing is necessary.

STATUS CONFERENCE

3. Motion of Debtor ATP Life Science Ventures, L.P., for Entry of an Order Confirming Its Rights with Respect to Portfolio Companies [Docket No. 1188 – filed September 30, 2026].

Response/Objection Deadline: October 7, 2026 at 4:00 p.m. (ET). Extended to October 9, 2026 at 4:00 p.m. (ET). Further extended for Apertor Pharmaceuticals, Inc., Evercrisp Biosciences, Inc., Initial Therapeutics, Inc., Marlinspike Therapeutics, Inc., Nereid Therapeutics Inc., Nine Square Therapeutics, Inc., and Red Queen Therapeutics, Inc. to October 13, 2026 at 4:00 p.m. (ET).

Related Documents:

A. Notice of Rescheduled Hearing on Motion of Debtor ATP Life Science Ventures, L.P., for Entry of an Order Confirming Its Rights with Respect to Portfolio Companies [Docket No. 1197 – filed October 06, 2026].

B. Non-Fund Debtors' Witness and Exhibit List for Hearing on October 19, 2026 at 2:00 P.M. [Docket No. 1225 – filed October 19, 2026].

C. Notice of Intent to Serve Subpoena Directed to Perry M. Mandarino [Docket No. 1249 – filed October 22, 2026].

Responses/Objections Received:

A. Objection by Apertor Pharmaceuticals, Inc., Evercrisp Biosciences, Inc., Initial Therapeutics, Inc., Marlinspike Therapeutics, Inc., Nereid Therapeutics Inc., Nine Square Therapeutics, Inc., and Red Queen Therapeutics, Inc. to Motion of Debtor ATP Life Science Ventures, L.P., for Entry of an Order Confirming its Rights with Respect to Portfolio Companies [Docket No. 1209 – filed October 13, 2026].

B. Reply of Debtor ATP Life Science Ventures, L.P. in Support of Its Motion for Entry of an Order Confirming Its Rights with Respect to Portfolio Companies [Docket No. 1210 – filed October 14, 2026].

Status: The parties will provide the Court with an update on the issues going forward at the hearing scheduled for November 10, 2026.

[Signature Page Follows]

Dated: October 26, 2026
Wilmington, Delaware

Respectfully submitted,

/s/ Halley S. Dannemiller

L. Katherine Good (No. 5101)
Brett M. Haywood (No. 6166)
Shannon A. Forshay (No. 7293)
Ethan H. Sulik (No. 7270)
Halley S. Dannemiller (No. 7562)
POTTER ANDERSON & CORROON LLP
1313 N. Market Street, 6th Floor
Wilmington, Delaware 19801
Telephone: (302) 984-6000
Facsimile: (302) 658-1192
Email: kgood@potteranderson.com
bhaywood@potteranderson.com
sforshay@potteranderson.com
esulik@potteranderson.com
hdannemiller@potteranderson.com

Andrew M. Berdon, Esq. (admitted *pro hac vice*)
Patricia B. Tomasco, Esq. (admitted *pro hac vice*)
Rachel E. Epstein, Esq. (admitted *pro hac vice*)
Alain Jaquet, Esq. (admitted *pro hac vice*)
Rachel Harrington, Esq. (admitted *pro hac vice*)
QUINN EMANUEL URQUHART & SULLIVAN, LLP
295 5th Avenue, 9th Floor
New York, New York 10016
Telephone: (212) 849-7000
Facsimile: (212) 849-7100
Email: andrewberdon@quinnemanuel.com
pattytomasco@quinnemanuel.com
rachelepstein@quinnemanuel.com
alainjaquet@quinnemanuel.com
rachelharrington@quinnemanuel.com

-and-

Eric D. Winston, Esq. (admitted *pro hac vice*)
Razmig Izakelian, Esq. (admitted *pro hac vice*)
Benjamin Roth, Esq. (admitted *pro hac vice*)
QUINN EMANUEL URQUHART & SULLIVAN, LLP
865 S. Figueroa Street, 10th Floor
Los Angeles, California 90017
Telephone: (213) 443-3000
Facsimile: (213) 443-3100
Email: ericwinston@quinnemanuel.com
razmigizakelian@quinnemanuel.com
benroth@quinnemanuel.com

Counsel to the Debtors and Debtors in Possession Other than the Fund Debtor

Dated: October 26, 2026
Wilmington, Delaware

Respectfully submitted,

/s/ R. Craig Martin

R. Craig Martin (DE No. 5032)
DLA PIPER LLP (US)
1201 North Market Street, Suite 2100
Wilmington, Delaware 19801
Telephone: (302) 468-5700
Facsimile: (302) 394-2341
Email: craig.martin@us.dlapiper.com

-and-

Gregory M. Juell (NY No. 5420120)
DLA PIPER LLP (US)
1251 Avenue of the Americas
New York, New York 10020
Telephone: (212) 335-4000
Facsimile: (212) 335-4501
Email: gregory.juell@us.dlapiper.com

-and-

Shant K. Eulmessekian (NY No. 6094668)
DLA PIPER LLP (US)
2000 Avenue of the Stars, Suite 400 North Tower
Los Angeles, California 90067
Telephone: (310) 595-3000
Facsimile: (310) 595-3300
Email: shant.eulmessekian@us.dlapiper.com

Counsel for the Fund Debtor